- Conditions
- Lung Cancer
- Interventions
- filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 202
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Limited Stage Small Cell Lung Cancer
- Interventions
- BMS-986489, Durvalumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 34
- States / cities
- Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more
- Conditions
- Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
- Interventions
- breath test, laboratory biomarker analysis
- Procedure · Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- carboplatin, etoposide, ifosfamide, topotecan hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Head and Neck Cancer, Lung Cancer
- Interventions
- cytology specimen collection procedure, immunohistochemistry staining method, sputum cytology, bronchoscopic and lung imaging studies, bronchoscopy, comparison of screening methods, endoscopic biopsy
- Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
- Interventions
- Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lung Cancer
- Interventions
- comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis, microarray analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, medical chart review, diagnostic bronchoscopy
- Genetic · Other · Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2016
- U.S. locations
- 4
- States / cities
- Nashville, Tennessee
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
- Interventions
- PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Huntsville, Alabama • Athens, Georgia • Hinsdale, Illinois + 3 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium, vinorelbine tartrate, standard follow-up care
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 93
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Burbank, California + 66 more
- Conditions
- Lung Cancer
- Interventions
- filgrastim, carboplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
- Conditions
- Cancer
- Interventions
- counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
- Other · Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • White River Junction, Vermont
- Conditions
- Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
- Interventions
- erlotinib hydrochloride, therapeutic endoscopic surgery, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- nicotine, Usual Care
- Drug · Behavioral
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1990
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma
- Interventions
- Contralateral Esophageal Sparing Technique (CEST)
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Newton, Massachusetts
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Questionnaire Administration, Tumor Treating Fields Therapy
- Other · Device
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Portland, Oregon
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- cis-diamminedichloroplatinum
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Lung Cancer
- Interventions
- Filgrastim, Pegfilgrastim, Etoposide, Cisplatin, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 14
- States / cities
- Gainesville, Florida • Miami Beach, Florida • Lexington, Kentucky + 10 more
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Interventions
- amifostine trihydrate, cisplatin, etoposide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 4
- States / cities
- Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
- Conditions
- Lung Cancer
- Interventions
- QS21, keyhole limpet hemocyanin, polysialic acid
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
- Interventions
- Bomedemstat, Atezolizumab
- Drug · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Anorexia, Cachexia, Lung Cancer
- Interventions
- megestrol acetate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Lung Cancer, NSCLC, Lung Adenocarcinoma
- Interventions
- Not listed
- Lead sponsor
- Myriad Genetic Laboratories, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- biospecimen collection
- Other
- Lead sponsor
- Addario Lung Cancer Medical Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Interventions
- dasatinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois